Status:

COMPLETED

Promoting Clinical Guidelines for Opioid Prescribing

Lead Sponsor:

University of Wisconsin, Madison

Collaborating Sponsors:

National Institute on Drug Abuse (NIDA)

Conditions:

Opioid Use

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study aims to understand the optimal sequencing and combination of implementation strategies that specific types of clinics and prescribers need to adopt clinical guidelines for opioid prescribin...

Detailed Description

The proposed study evaluates a sequence and combination of implementation strategies that is tailored to the needs of stakeholders at different levels (health system, clinic, and prescriber). We will ...

Eligibility Criteria

Inclusion

  • Clinics will be eligible for the study if they:
  • are a primary care clinic (non-pediatric primary care, internal medicine, or family medicine);
  • have not received the systems consultation intervention;
  • do not explicitly prohibit initiating opioid therapy;
  • do not exceed the performance on key measures of guideline concordance (fewer than 80% of long-term opioid patients have treatment agreements and a urine drug screen in the past 12 months)
  • Prescribers will be eligible if they:
  • are a primary care provider at the clinic;
  • are not temporary providers who do not manage stable panels or patients;
  • While patients are not subjects of study, de-identified prescriber panel data will be used to assess outcome measures. To be included in the de-identified prescriber panel data, patients must:
  • have a primary care provider at the clinic;
  • are prescribed opioid therapy for at least 3 consecutive months;
  • do not have a cancer diagnosis or are receiving hospice care.

Exclusion

  • Clinics will be excluded if they are not a primary care clinic, have received the systems consultation intervention, prohibit initiating opioid therapy, or exceed the threshold on key measures of guideline concordance.
  • Prescribers will be excluded if they don't have prescribing privileges or are temporary providers who do not manage stable panels or patients.
  • De-identified prescriber panel data will be excluded from outcome measures if they do not have a primary care provider at the clinic, are not prescribed opioid therapy for at least 3 consecutive months, or have a cancer diagnosis or are receiving hospice care.

Key Trial Info

Start Date :

January 31 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2022

Estimated Enrollment :

268 Patients enrolled

Trial Details

Trial ID

NCT04044521

Start Date

January 31 2020

End Date

September 1 2022

Last Update

June 17 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Bellin Health Systems

Green Bay, Wisconsin, United States, 54305

2

UW Health

Madison, Wisconsin, United States, 53792